RecruitingNCT05979675
Acute Myeloid Leukemia Registry
Acute Myeloid Leukemia Registry - Prospective National Multicentric Observational Study
Sponsor
Turkish Hematology Association
Enrollment
250 participants
Start Date
Dec 21, 2021
Study Type
OBSERVATIONAL
Conditions
Summary
All acute myeloid leukemia (AML) patients diagnosed after 1 Jan 2020 will be included to this study.
Eligibility
Min Age: 18 Years
Inclusion Criteria2
- Diagnosed as AML after 1 Jan 2020
- Patients signed informed consent form
Exclusion Criteria1
- Patients under 18 years old
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05979675
Related Trials
Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)
NCT05554393175 locations
Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)
NCT06672146112 locations
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
NCT05564390331 locations
Testing the Combination of an Anti-Cancer Drug, Iadademstat, With Other Anti-Cancer Drugs (Venetoclax and Azacitidine) for Treating AML
NCT065142614 locations
Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)
NCT06317649218 locations